Overview

Update
IPO / Stock
Went Public on Jul 10, 2014 / EBR:ARGX
Total Equity Funding
$61.95M in 3 Rounds from 11 Investors
Headquarters:
Rotterdam
Description:
arGEN-X has invented and developed a platform for antibody lead choice in the discovery of human antibody therapeutics.
Founders:
Categories:
Therapeutics, Biotechnology, Clinical Trials
Website:
http://www.argen-x.com
Social:

Company Details

Update

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics.

Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

Funding Rounds (5) - $97.16M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jun, 2016€30M / Post Ipo Equity4
May, 2015€1.5M / Grant0
Dec, 2011€32.5M / Series B7
Feb, 2010$4.5M / Series A7
Sep, 2009$13.6M / Series A4

Current Team (5)

Update

Offices/Locations (1)

Update
  • HQ

    Dr Molewaterplein 50

    Rotterdam, 3015

    NLD

Images (1)

Update

Add Acquisitions

Add Board Members and Advisors

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos